--- title: "EU Grant Programs | QbD Group" description: "QbD Group supports life sciences consortia across EU-funded programs. Regulatory, clinical and quality expertise across Europe, from proposal to market access." url: https://qbdgroup.com/en/eu-grants type: "Page" language: en publisher: "QbD Group" citation: "QbD Group, \"EU Grant Programs | QbD Group\", https://qbdgroup.com/en/eu-grants" --- EU-Funded Initiatives # Your Strategic Partner for EU Grant Programs QbD Group helps life sciences consortia meet regulatory, clinical and quality requirements across EU-funded projects. From proposal stage through market access, your team gains a single partner with deep European roots and end-to-end capabilities. [Talk to our team](https://qbdgroup.com/en/contact) 700+ Life sciences experts 10+ Countries with legal entities 1,200+ Clients supported 15 years Track record Why QbD Group ## Built for the complexity of EU-funded programs EU grants demand partners who bring regulatory expertise, operational flexibility, and multi-country presence. QbD Group delivers all three. ### Legal entities across Europe Registered entities in Belgium, the Netherlands, Spain, France, the UK, Switzerland and more. Flexible invoicing and cost allocation as required by EU grant structures. ### End-to-end service offering Regulatory affairs, clinical trials, qualification and validation, quality assurance, and market access. One partner covers every stage of the project. ### MD, IVD and biotech expertise Specialised teams for medical devices (MDR), in vitro diagnostics (IVDR), pharmaceuticals and advanced therapies. Domain-specific knowledge from day one. ### Strong references and track record 1,200+ clients supported since 2011. From startups in first-in-human trials to global companies managing complex portfolios across EU markets. Case in point ## Part of the €24M EU-funded RANGER program QbD Group is part of the RANGER consortium, an EU-funded program led by Ginkgo Bioworks and supported through the EU4Health programme. We support the IVDR certification track of an in vitro diagnostic for respiratory pathogens, contributing across software, quality, regulatory affairs and clinical (CRO) services. Clinical performance studies will be run at four EU hospitals: KU Leuven (Belgium), Karolinska University Hospital (Sweden), Leiden University Medical Center (Netherlands) and Tartu University Hospital (Estonia). - Funder - HaDEA / EU4Health (HERA priorities) - Lead - Ginkgo Bioworks - Duration - 4 years, 3 phases - QbD Group scope - Software, QA, RA, Clinical (CRO) - Active since - February 2025 [Read the full announcement](https://www.qbdgroup.com/en/about-qbd/projects/ranger) What we deliver ## Services across the EU consortium lifecycle QbD Group supports consortia across the full lifecycle, from development and certification through post-market activities. Services are activated as your program reaches each phase. Not every service is needed at once, and we scale our involvement to match your project's stage. Phase 01 ### Development & Quality - Regulatory strategy and submissions (MDR, IVDR, pharma) - Quality management system setup and auditing - Qualification and validation (GxP environments) - Toxicology and environmental risk assessments Phase 02 ### Certification & Trials - EU certification and notified body interaction - Clinical performance study design, management and CRO services Phase 03 ### Post-Market - Person Responsible for Regulatory Compliance (PRRC) - Post-market surveillance and vigilance Get in touch ## Planning an EU grant application? QbD Group strengthens your consortium with regulatory expertise, clinical capabilities, and multi-country presence. Let's talk about how we fit your program. [Contact us](https://qbdgroup.com/en/contact) --- Source: https://qbdgroup.com/en/eu-grants — © QbD Group. Quote freely with attribution and a link back.